NeoPharm, Inc. was founded in 1990 and is headquartered in Lake Bluff, Illinois. NeoPharm, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases primarily in the United States. Its products include LEP-ETU, which is in Phase II trial for the treatment of breast and ovarian cancer; LE-DT that is in Phase I trial for the treatment of various forms of cancer; and LE-rafAON, which completed preclinical studies to treat pancreatic cancer. The company has a co-operative research and development agreement with the National Institute of Neurological Diseases and Stroke for research on a therapeutic agent for untreatable brain diseases in humans. NeoPharm would provide its proprietary drug, Cintredekin Besudotox (IL13-PE38QQR), and technical resources to study its effects in various brain cancers in humans. Its IL13-PE38QQR also completed preclinical studies for the treatment of idiopathic pulmonary fibrosis and asthma. The company was formerly known as OncoMed, Inc. and changed its name to NeoPharm, Inc. in March 1995.

Formerly known as Stone Electronic Technology Limited, Stone Group Holdings Limited (Stock code: 409) was established on September 3, 1987. After a successful restructuring exercise in 1993, the Company became the first non-state-owned share-holding company in the PRC listed on the Stock Exchange of Hong Kong in August 1993. It is principally engaged in IT electronic & media – related business in mainland China, healthcare products business and investment business.The Company's IT electronic and media-related business includes the manufacture and distribution of traditional electronic products and the operation of internet café chain. Electronic products include dot matrix printer and value-added tax control machine with patented intellectual property, and the Group also acts as the agent and distributor of industrial controllers, uninterrupted power system equipment, digital graphics, semiconductors, computers etc.. Product coverage includes SIEMENS, FUJI. The internet café chain – Sunnet café is located in Guangdong Province.

Soft Gel Technologies, Inc. company makes hermetically sealed gelatin encapsulations of dietary supplements -- vitamins, minerals, fatty acids, and herbal extracts. The company manufactures more than 150 products, both private label and branded, to promote digestive health, immune system support, urinary tract wellness, and weight loss. Its brands include Carnisol, Femalgen, GlucoFit, and LyCoQ. Soft Gel Technologies also provides contract research and development, formulation, manufacturing, and sales and marketing services for other nutritional products companies. Soft Gel company is owned by Japanese chemicals firm Kenko.

Sanofi Pasteur makes vaccines for 20 infectious viral and bacterial diseases, such as diptheria, hepatitis A and B, meningitis, polio, tetanus, and whooping cough. It's also the world's largest maker of the dreaded flu shot, with a 40% market share. The company has more than 15 other vaccines in development, including an HIV vaccine and a combination booster shot to protect against six childhood diseases. Sanofi Pasteur has manufacturing facilities across France and the US, as well as in Argentina, Canada, China, and Thailand. The company is a subsidiary of pharmaceutical giant Sanofi-Aventis.

Servier is an independent, French pharmaceutical company which manufactures and sells drugs to combat cardiovascular diseases, such as coronary artery disease, hypertension, and stroke. Cardiovascular drugs account for about two-thirds of the company's annual revenues. It also produces medicines to treat diabetes, venous disease, and cancer. Annually, more than 700 million boxes of drugs are produced by Servier. Its pharmaceutics can be found in 140 countries; 80% of its sales are generated internationally.

Neurocrine Biosciences, Inc. was founded in 1992 and is based in San Diego, California. Neurocrine Biosciences, Inc. engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company develops drugs for endometriosis, anxiety, depression, pain, diabetes, irritable bowel syndrome, insomnia, and other neurological and endocrine related diseases and disorders. Its products in clinical development comprise Elagolix, a Phase II product for Endometriosis; CRF1 Antagonist, a phase II product for mood disorders; CRF2 Peptide Agonist, a phase II drug for Cardiovascular related diseases; CRF1 Antagonist, a Phase I product for treating Mood Disorders and Irritable Bowel Syndrome; and Elagolix, a Phase I product for treating Benign Prostatic Hyperplasia and Uterine Fibroids. The company's research programs include Vesicular Monoamine Transporter 2 Inhibitor for movement disorders and schizophrenia; Glucose Dependent Insulin Secretagogues for type II diabetes; Antiepileptic drugs for epilepsy and bipolar disorder; and GnRH Antagonists for hormone dependent diseases and oncology. It has strategic alliances with GlaxoSmithKline to develop and commercialize CRF antagonists for psychiatric, neurological, and gastrointestinal diseases; and Dainippon Sumitomo Pharma Co. Ltd. to develop and commercialize indiplon in Japan.

Actelion Ltd is a Swiss biopharmaceutical company with a global presence that focuses on the discovery, development and commercialization of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium, the single layer of cells separating every blood vessel from the blood stream. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second product, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. Ventavis, the third product, is an inhaled synthetic analogue of prostacyclin that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits.

Lyne Laboratories contract pharmaceutical manufacturer specializes in oral liquid formulations (with a bitter-taste blocker available), as well as powder-form, semi-solid, and tablet medicines. The company also offers analytical services, such as quality control and testing, and regulatory support services. Lyne Laboratories can whip up small test-size batches for clinical research as well as full production for commercial launches and provide regulatory support along the way. An explosion-proof production and storage facility has expanded its ability to produce flammable drugs.

STADA Arzneimittel AG (STADA) is a Germany-based company active in the pharmaceutical sector, concentrating on the development and marketing of products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are: Generics, comprised of low-priced and active-ingredient products, and Branded Products, focusing on multisource products that are accessible without active ingredient research. STADA’s generic drugs are marketed by the Group subsidiary, STADApharm GmbH, through a sales network including Austria, Belgium, Bosnia, Portugal and the United Kingdom. Its branded products are distributed internationally as well, in such countries as Bulgaria, the Czech Republic, Denmark, Russia, Thailand and Vietnam. The Company operates through subsidiaries located in Germany, Switzerland, Russia, Macedonia, Serbia, Montenegro, Bulgaria, Romania and Poland, as well as in the United States.

Experimental and Applied Sciences (EAS) makes and distributes dietary supplements and weight-management products worldwide. The firm's shakes, nutrition bars, protein drinks, and nutritional supplements -- branded as AdvantEdge, Catapult, EAS, Muscle Armor, and Myoplex -- fuel dieters, body builders, and other athletes. EAS also sells training and exercise videos as well as best-selling book, Body for Life (written by one-time owner Bill Phillips). EAS is part of Abbott Nutrition, a division of leading health care products maker Abbott Laboratories.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.